Screening for SARS‐CoV ‐2 antibodies in convalescent plasma in Brazil: Preliminary lessons from a voluntary convalescent donor program-Reference-Cited by-同舟云学术

Screening for SARS‐CoV ‐2 antibodies in convalescent plasma in Brazil: Preliminary lessons from a voluntary convalescent donor program

Published:2020-09-16 Issue:12 Volume:60 Page:2938-2951
ISSN:0041-1132
Container-title:Transfusion
language:en
Short-container-title:Transfusion

Author:

Wendel Silvano¹^ORCID,Kutner Jose Mauro²,Machado Rafael³,Fontão‐Wendel Rita¹,Bub Carolina²^ORCID,Fachini Roberta¹,Yokoyama Ana²,Candelaria Gabriela¹,Sakashita Araci²,Achkar Ruth¹,Hamerschlak Nelson²,Scuracchio Patricia¹,Amaral Marcelo¹,Dal Ben Mirian⁴,Araujo Danielle³,Soares Camila³,Camargo Anamaria⁴,Kallás Esper⁵,Durigon Edison³,Reis Luiz Fernando⁴,Rizzo Luiz Vicente⁶

Affiliation:

1. Hospital Sírio‐Libanês Blood Bank São Paulo Brazil

2. Hospital Israelita Albert Einstein Blood Bank São Paulo Brazil

3. Department of Microbiology Institute of Biomedical Sciences, University of Sao Paulo São Paulo Brazil

4. Hospital Sírio‐Libanês São Paulo Brazil

5. Infectious Disease Department University of São Paulo Medical School São Paulo Brazil

6. Albert Einstein Jewish Institute for Education and Research São Paulo Brazil

Publisher

Wiley

Subject

Hematology,Immunology,Immunology and Allergy

Link

https://onlinelibrary.wiley.com/doi/pdf/10.1111/trf.16065

Reference82 articles.

1. World Health OrganizationNaming the coronavirus disease (COVID‐19) and the virus that causes it. Available athttps://www.who.int/emergencies/diseases/novel‐coronavirus‐2019/technical‐guidance/naming‐the‐coronavirus‐disease‐(covid‐2019)‐and‐the‐virus‐that‐causes‐it. Accessed June 2 2020.

2. Clinical features of patients infected with 2019 novel coronavirus in Wuhan, China

3. The origin, transmission and clinical therapies on coronavirus disease 2019 (COVID-19) outbreak – an update on the status

4. Characteristics of and Important Lessons From the Coronavirus Disease 2019 (COVID-19) Outbreak in China

5. World Health Organization (WHO)Clinical management of COVID‐19. Interim guidance 27 May 2020 – WHO/2019‐nCoV/clinical/2020.5.https://www.who.int/publications-detail/clinical-management-of-covid-19. Accessed August 2 2020.

Cited by 55 articles. 订阅此论文施引文献订阅此论文施引文献，注册后可以免费订阅5篇论文的施引文献，订阅后可以查看论文全部施引文献

1. Development and characterization of a multimeric recombinant protein using the spike protein receptor binding domain as an antigen to induce SARS‐CoV‐2 neutralization;Immunity, Inflammation and Disease;2024-07

2. Immune Evasion of SARS-CoV-2 Omicron Subvariants XBB.1.5, XBB.1.16 and EG.5.1 in a Cohort of Older Adults after ChAdOx1-S Vaccination and BA.4/5 Bivalent Booster;Vaccines;2024-01-30

3. Neutralizing antibody response after immunization with a COVID‐19 bivalent vaccine: Insights to the future;Journal of Medical Virology;2024-01-29

4. SARS-CoV-2 Nanovaccine Composed of Microfluidic-Produced Gold Nanoparticles Induces Neutralizing Immune Responses;ACS Applied Nano Materials;2023-12-05

5. Intranasal Liposomal Formulation of Spike Protein Adjuvanted with CpG Protects and Boosts Heterologous Immunity of hACE2 Transgenic Mice to SARS-CoV-2 Infection;Vaccines;2023-11-20